OrbiMed Advisors Increases Stake in Traws Pharma to 11.9% via Private Placement

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC have filed Amendment No. 3 to their Schedule 13D for Traws Pharma, Inc. (TRAW), reporting an increased beneficial ownership position. On April 16, 2026, OrbiMed Private Investments VIII, LP (OPI VIII) participated in a private placement, purchasing 597,729 shares along with various series of warrants. Currently, the reporting persons beneficially own 1,876,198 shares, which represents 11.9% of the issuer's outstanding common stock. This total includes 1,203,260 directly held shares and 672,938 shares issuable upon the conversion of Series C Non-Voting Convertible Preferred Stock. The filing also notes the acquisition of 2024 and 2026 Series warrants and pre-funded warrants, which are not currently exercisable or are excluded from the immediate beneficial ownership count due to specific conversion limitations. OrbiMed Advisors exercises voting and investment power over these securities through a management committee. The reporting persons may further adjust their holdings based on ongoing evaluations of the issuer's performance and market conditions.